Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
NCT06549959

A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

Led by RemeGen Co., Ltd. · Updated on 2024-08-12

248

Participants Needed

3

Research Sites

21 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to evaluate the Pharmacokinetics and safety of Telitacicept Pre-filled Injection and Freeze-dried powder Injection.

CONDITIONS

Official Title

A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

Who Can Participate

Age: 18Years - 50Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 to 50 years old at the time of consent, any gender
  • Male weight between 55 and 70 kg, female weight between 50 and 65 kg
  • Body mass index (BMI) between 18 and 28 kg/m2, including limits
  • Normal or clinically insignificant abnormal physical exam, vital signs, chest X-ray, ECG, epidemiologic tests, blood tests, biochemistry, lipids, urinalysis, and coagulation
  • Able to understand study purpose and procedures, voluntarily agree to participate, and sign informed consent
  • Able to complete all study procedures as required
Not Eligible

You will not qualify if you...

  • Site staff, sponsor staff, or their family members involved in the trial
  • History of nervous, cardiovascular, digestive, respiratory, urinary, blood, muscle, immune, metabolic diseases, mental illness, or cancer
  • History or signs of lymphoproliferative diseases such as lymphoma or leukemia
  • History of abnormal bleeding, coagulation disorders, blood clots, or long-term use of anticoagulants or antiplatelet drugs
  • Abnormal ECG findings including prolonged QTc interval or significant blocks
  • First-degree relatives with inherited immunodeficiency
  • Current allergies or history of allergies to protein products, alcohol, or multiple drugs/non-drug factors
  • Surgery within 6 months before screening or planned surgery during the trial
  • Participation in another drug trial within 3 months before screening
  • Use of drugs affecting liver metabolism within 4 weeks before randomization or during the trial
  • Use of any medications, including herbal or vitamins, within 14 days before randomization
  • History of significant blood donation or bleeding within 3 months before screening or plans to donate blood within 1 month after trial
  • Positive alcohol breath test or history of alcoholism in past 6 months or inability to stop drinking during trial
  • Smoking more than 5 cigarettes per day in past 6 months or inability to quit during trial
  • Excessive caffeine intake within 4 weeks before screening
  • History of drug abuse or dependence within 5 years before screening
  • Use of weight-loss drugs, excessive dieting, or overeating during trial
  • Tattoos, scars, or conditions at planned injection site
  • COVID-19 vaccine within 2 weeks before randomization or live vaccine within 30 days before or during trial
  • Positive tests for hepatitis B, hepatitis C, HIV, syphilis, or tuberculosis
  • History of serious infections in past 6 months
  • Recent or multiple episodes of herpes zoster or herpes simplex infections
  • Female pregnancy, lactation, or unwillingness to use effective contraception during and 4 months after trial
  • Other investigator-determined factors unsuitable for trial participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

The Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, China, 550004

Actively Recruiting

2

West China Hospital of Sichuan University

Chengdu, Sichuan, China, 610041

Actively Recruiting

3

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China, 300191

Actively Recruiting

Loading map...

Research Team

B

Binghua Xiao

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here